Sign Out
Combination therapy with bicalutamide 50 mg: Treatment of advanced prostate cancer in combination with luteinising hormone-releasing hormone (LHRH) analogue therapy or surgical castration.
Monotherapy with 3 tablets of bicalutamide 50 mg (150 mg bicalutamide): Bicalutamide at a dose of 150 mg is indicated either alone or as adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression (see Pharmacology: Pharmacodynamics under Actions).
Continue with Google